Dr. Veerappan Subramanian has over 30 years of experience in the pharmaceutical industry, has developed and commercialized more than 200 specialty drug products, and is credited as a business pioneer in the area of generic pharmaceuticals. Prior to founding Odin Pharmaceuticals, he established the development and marketing companies Novel Laboratories and GAVIS Pharmaceuticals in 2008, developing over 100 ANDAs in the controlled drugs, semi-solids, and inhalations forms, commercializing revenues of over $100 million prior to acquisition by Lupin Pharmaceuticals in 2015. Prior to founding Novel and GAVIS, Dr.Subramanian founded Kali Laboratories in 1997, specializing in immediate release, modified release, and controlled drug products and filing over 50 ANDAs prior to its acquisition by Par Pharma in 2005. Prior to becoming an entrepreneur, Dr. Subramanian has held numerous executive and leadership positions at IVAX/Zenith Laboratories, Purepac, Johnson & Johnson, Richardson Vicks, and Squibb. Dr. Subramanian received his Ph.D. in Pharmacy from Rutgers University in 1981 and has both a Bachelors and a Masters in Pharmacy. He is a registered pharmacist in New York and New Jersey.
Dr. Ilango Subramanian is President of Odin Pharmaceuticals. In this role, Dr. Subramanian is responsible for R&D, Operations, and overall administration of the company. Prior to joining the Odin, Dr.Subramanian held a number of leadership positions at Novel Laboratories and GAVIS Pharmaceuticals from 2010 to 2015 as Vice President, responsible for Corporate Development, Biopharmaceutics, Medical Affairs, and Project Management. As a cross-functional executive, Dr.Subramanian coordinated the Novel and GAVIS teams in development of over 100 drug products and commercialization of 25 drug products as well as creating strategic development alliances with R&D organizations in softgel and transdermal drug technologies. Prior to this, Dr.Subramanian served as a Project Manager at Publicis Healthcare and a Consultant for BGB Healthcare Group. Dr. Subramanian received a Doctor of Pharmacy from Rutgers University Ernest Mario School of Pharmacy in 2009 and a Masters in Business Administration from New York University Stern School of Business in 2014. He is a registered pharmacist in New Jersey.
Chief Financial Officer
Arshad Kagalwalla is an accounting executive with over 20 years of experience in Finance & Accounting and 15 years in the generic pharmaceutical industry. Mr. Kagalwalla joined Odin Pharmaceuticals in 2018 as CFO and is responsible for all Accounting and Finance functions of the company, including financial planning and analysis, budgeting and forecasting, taxation and revenue management. Prior to this, Mr.Kagalwalla served as CFO at Somerset Therapeutics from 2016. Prior to joining Somerset, Arshad was Head of Finance and Accounting at Novel Laboratories and GAVIS Pharmaceuticals and has served as an accounting executive for Par Pharmaceuticals and Kali Laboratories. Mr.Kagalwalla receiving a CPA in 2004 following work as a public accountant. Mr.Kagalwalla has a Bachelors in Commerce and is a Chartered Accountant in India.
Vice President, Quality & Regulatory Affairs
Scott Talbot joined Odin in June of 2019 as the Vice President of Quality Assurance & Regulatory Affairs. In this role, Mr.Talbot manages all regulatory and quality operations within the company. Mr.Talbot brings to Odin over 30 years of quality and compliance experience with extensive expertise in sterile facility compliance with the FDA. Before joining Odin, Scott served as Vice President of Quality and Regulatory Affairs for Slayback Pharma. Prior to Slayback, Mr.Talbot held management positions at Baxter Healthcare, Bausch & Lomb Pharmaceuticals, Teva, and Actavis. He has worked closely with FDA district offices in Puerto Rico, Florida, Kansas, and New Jersey on behalf of facilities in those districts, successfully resolving issues raised by FDA warning letters sent to these facilities. Scott holds bachelor’s degrees in biology and chemistry from Illinois State University.
Vice President, Product Development
Dr. Mandar Shah joined Odin in 2018 as Vice President of Product Development and is responsible for the development of ANDAs from inception to submission. Mandar has previously worked as a research executive for large pharma companies Bristol-Myers Squibb (1991 to 1993), Alcon (1996 to 2004), Pfizer (2004 to 2006) and J&J (2006 to 2012) as well as generic companies Ranbaxy (1994 to 1995), Sentiss (2012 to 2016) and West-Ward (2016 to 2017). In a career spanning more than 20 years in the pharma industry, Dr. Shah has developed an extensive array of sterile products and sterile product intellectual property. He specializes in developing non-infringing, difficult-to-formulate, difficult to manufacture, and complex generic products. He is also an inventor of over 20 patents filed or granted at the US Patent and Trademark Office and has developed a niche expertise in the Evergreening of the Patents- improving bioavailability, stability, manufacturing processes, and other critical parameters of known drugs to create new intellectual property. Dr. Shah obtained a Ph.D. degree in Pharmaceutical Chemistry from The University of Kansas in 1991, an Masters degree in Pharmaceutics from The University of Louisiana in 1985 and a Bachelors in Pharmacy degree from The Gujarat University in 1981.
Dr. Aman Trehan joined Odin as the Vice President of Global Intellectual Property and Product Strategy. He manages all activities related to Intellectual property and Product Portfolio within the company. He has around 15 years of experience in this field in many pharmaceutical companies. He started his career with Ranbaxy Labs followed by leadership positions at Wockhardt, Alembic, Zydus and Novel Labs. In his last assignment with Lupin, he was the Site Head of IP at Lupin Somerset. He has successfully handled many Hatch Waxman litigations during his career in different companies and received Hatch Waxman impact case of the year award as well. He has also received “Top IP Leaders” award in 2020. Dr. Trehan holds Ph.D. degree in Pharmaceutics. He obtained certification on Prescription Drug Regulations, Cost and Access from Harvard University.
Analytical Research and Quality Executive
Swapan directs the company’s analytical services and quality control departments. He has experience in both day-to-day management and long-term process improvement, and bears the significant responsibility of ensuring compliance with regulatory, health, safety, and environmental guidelines, policies, and procedures.
Roy has more than 30 years experience in the pharmaceutical industry and has leveraged his technical expertise and management skills at many successful generic pharmaceutical companies including Actavis, Par Pharmaceuticals, Zenith/Goldline Pharmaceuticals and Purepac Pharmaceutical Co. An industry veteran, Roy has developed analytic tests and quality systems for over one hundred ANDA submissions. Roy holds a master’s of business administration, focusing on general management, from Rutgers University.